Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 6/2015

01.06.2015 | Original Article

Predictors of Long-Term Diabetes Remission After Metabolic Surgery

verfasst von: Ming Hsien Lee, Wei-Jei Lee, Keong Chong, Jung-Chien Chen, Kong-Han Ser, Yi-Chih Lee, Shu-Chun Chen

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background Data

Bariatric/metabolic surgery has been proposed for the treatment of inadequately controlled type 2 diabetes mellitus (T2DM) in obese patients. However, prediction on successful long-term remission of T2DM after metabolic surgery has not been clearly studied. Our objectives were to evaluate rates of long-term remission of T2DM after metabolic surgery and determine the independent predictors of remission.

Methods

Outcomes of 157 patients who underwent metabolic surgery between 2006 and 2009 and who had complete 5-year follow-up data were assessed. Prolonged complete remission was defined as glycated hemoglobin (HbA1c) less than 6 % without diabetes medication up to 5 years. Predictors of prolonged remission studies included patient characteristics such as glucose level, HbA1c, body weight, waist circumference, blood pressure, total cholesterol, LDL, triglyceride, uric acid, AST, alanine transaminase (ALT), albumin, insulin, C-peptide, iron, calcium, complete blood cell count, the ABCD score (a multidimensional grading system composed of age, body mass index (BMI), C-peptide levels, and duration of T2DM), and postoperative weight loss.

Results

At 5 years after surgery, the weight loss was 27.1 % and the mean BMI decreased from 39.8 to 28.8 kg/m2. The mean HbA1c decreased from 8.3 to 6.0 %. A significant number of patients had improvement in their glycemic control, including 97 (71.3 %) patients who had complete remission (HbA1c < 6.0 %), 27 (19.9 %) partial remission (HbA1c < 6.5 %), and 12 (8.8 %) improved condition (HbA1c < 7 %). In univariate analysis, patients with prolonged T2DM remission after surgery were younger and heavier; had a wider waist, higher C-peptide, shorter duration of T2DM, higher liver enzyme, higher insulin resistance, higher C-peptide level, and higher white blood cell count; were taking smaller insulin dosage; had higher ABCD score; and had greater weight loss than those without remission. Multivariate logistical regression analyses showed that the ABCD score and weight loss were the only predictors of remission after metabolic surgery.

Conclusions

Metabolic surgery is a treatment option for patients with obesity and T2DM. Baseline ABCD score and weight loss have a major influence on outcome.
Literatur
1.
Zurück zum Zitat Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. JAMA 2013; 414:782–787. Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. JAMA 2013; 414:782–787.
2.
Zurück zum Zitat Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.CrossRefPubMed Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.CrossRefPubMed
3.
Zurück zum Zitat The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545–2559.CrossRef The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545–2559.CrossRef
4.
Zurück zum Zitat Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–958.CrossRefPubMed Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–958.CrossRefPubMed
5.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.CrossRefPubMedCentralPubMed Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Hiroki Yokoyam, Okudaira M, Otani T, et al. High incidence of diabetic nephropath in early-onset Japanese NIDDM patients. Diabetes Care 1998;7:1080–1085CrossRef Hiroki Yokoyam, Okudaira M, Otani T, et al. High incidence of diabetic nephropath in early-onset Japanese NIDDM patients. Diabetes Care 1998;7:1080–1085CrossRef
7.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.CrossRefPubMed
8.
Zurück zum Zitat Sjostrom L, Narbro K, Sjostrom D, et al. Effect of bariatric surgery on mortality in Swedish obese subjects. NEJM 2007;357:741–752.CrossRefPubMed Sjostrom L, Narbro K, Sjostrom D, et al. Effect of bariatric surgery on mortality in Swedish obese subjects. NEJM 2007;357:741–752.CrossRefPubMed
9.
Zurück zum Zitat Lee WJ, Huang MT, Wang W, et al. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005;15:751–757.CrossRefPubMed Lee WJ, Huang MT, Wang W, et al. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005;15:751–757.CrossRefPubMed
10.
11.
Zurück zum Zitat Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316–323PubMed Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316–323PubMed
12.
Zurück zum Zitat Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146:143–148.CrossRefPubMed Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146:143–148.CrossRefPubMed
13.
Zurück zum Zitat Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567–1576.CrossRefPubMedCentralPubMed Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567–1576.CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial. JAMA 2013;309(21):2240–2249.CrossRefPubMedCentralPubMed Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial. JAMA 2013;309(21):2240–2249.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Liang Z, Wu Q, Chen B, Yu P, Zhao H, Quyang X. Effect of laparoscopic Roux-en-Y gastric bypass for type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Prac 2013;101(1):50–56.CrossRef Liang Z, Wu Q, Chen B, Yu P, Zhao H, Quyang X. Effect of laparoscopic Roux-en-Y gastric bypass for type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Prac 2013;101(1):50–56.CrossRef
16.
Zurück zum Zitat Wentworth J, Playfair J, Lavrie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomized controlled trial. Lancet Diabetes Endocrinol 2014;2(7):545–52. Wentworth J, Playfair J, Lavrie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomized controlled trial. Lancet Diabetes Endocrinol 2014;2(7):545–52.
17.
Zurück zum Zitat Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2014;370(21):2002–2013CrossRefPubMed Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2014;370(21):2002–2013CrossRefPubMed
18.
Zurück zum Zitat Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.CrossRefPubMed Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.CrossRefPubMed
19.
Zurück zum Zitat DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010;6:249–253.CrossRefPubMed DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010;6:249–253.CrossRefPubMed
20.
Zurück zum Zitat Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254–259.CrossRefPubMed Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254–259.CrossRefPubMed
21.
Zurück zum Zitat Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5–S20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5–S20.
23.
Zurück zum Zitat Matthews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–419.CrossRefPubMed Matthews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–419.CrossRefPubMed
24.
Zurück zum Zitat Lee WJ, Yu PJ, Wang W, et al. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg 2005;242:20–28CrossRefPubMedCentralPubMed Lee WJ, Yu PJ, Wang W, et al. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg 2005;242:20–28CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Ser KH, Lee WJ, Lee YC, Chen JC, Su YH, Chen SC. Experience in laparoscopic sleeve gastrectomy for morbidly obese Taiwanese: staple-line reinforcement is important for preventing leakage. Surg Endosc 2010;24(9):2253–2259.CrossRefPubMed Ser KH, Lee WJ, Lee YC, Chen JC, Su YH, Chen SC. Experience in laparoscopic sleeve gastrectomy for morbidly obese Taiwanese: staple-line reinforcement is important for preventing leakage. Surg Endosc 2010;24(9):2253–2259.CrossRefPubMed
26.
Zurück zum Zitat Lee WJ, Hur K, Lakadawala M, Kasama K, et al. Predicting the Success of Metabolic Surgery: Age, Body Mass Index, C-peptide, and Duration Score. Surg Obes Relat Dis 2013; 9: 379–384.CrossRefPubMed Lee WJ, Hur K, Lakadawala M, Kasama K, et al. Predicting the Success of Metabolic Surgery: Age, Body Mass Index, C-peptide, and Duration Score. Surg Obes Relat Dis 2013; 9: 379–384.CrossRefPubMed
27.
Zurück zum Zitat Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes care. 2013;36(1):20–26.CrossRefPubMedCentralPubMed Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes care. 2013;36(1):20–26.CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Dixon J, Hur KY, Lee WJ, et al. Gastric bypass in type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet. Med. 2013; 30: e127–e134.CrossRefPubMed Dixon J, Hur KY, Lee WJ, et al. Gastric bypass in type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet. Med. 2013; 30: e127–e134.CrossRefPubMed
29.
Zurück zum Zitat Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA 2013;309:2250–2261.CrossRefPubMed Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA 2013;309:2250–2261.CrossRefPubMed
30.
Zurück zum Zitat Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 Kg/m2: An endocrinologist’s perspective. Obesity Surg 2013;23:800–808.CrossRef Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 Kg/m2: An endocrinologist’s perspective. Obesity Surg 2013;23:800–808.CrossRef
31.
Zurück zum Zitat Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diab Care 2012;35:1420–1426.CrossRef Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diab Care 2012;35:1420–1426.CrossRef
32.
Zurück zum Zitat Lakadawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30–35) Indian patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2013;9:370–378.CrossRef Lakadawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30–35) Indian patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2013;9:370–378.CrossRef
33.
Zurück zum Zitat Brethauer SA, Amino A, Ramero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628–637.PubMedCentralPubMed Brethauer SA, Amino A, Ramero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628–637.PubMedCentralPubMed
34.
Zurück zum Zitat Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.CrossRefPubMed Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.CrossRefPubMed
35.
Zurück zum Zitat Sultan S, Gupta D, Parikh M, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2010;6:373–376.CrossRefPubMed Sultan S, Gupta D, Parikh M, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2010;6:373–376.CrossRefPubMed
36.
Zurück zum Zitat Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 2013;216:545–545.CrossRefPubMed Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 2013;216:545–545.CrossRefPubMed
37.
Zurück zum Zitat Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013;9:7–14.CrossRefPubMed Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013;9:7–14.CrossRefPubMed
38.
Zurück zum Zitat Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 202;308:1122–1131. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 202;308:1122–1131.
39.
Zurück zum Zitat Dixon JB, O’Brien PE. Selecting the optimal patient for LAP-BAND placement. Am J Surg 2002;184:17–20.CrossRef Dixon JB, O’Brien PE. Selecting the optimal patient for LAP-BAND placement. Am J Surg 2002;184:17–20.CrossRef
40.
Zurück zum Zitat Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237:751–758.PubMedCentralPubMed Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237:751–758.PubMedCentralPubMed
41.
Zurück zum Zitat Hamza N, Abbas MH, Darwish A, Shafeek Z, New J, Ammori BJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis 2011;7:691–696.CrossRefPubMed Hamza N, Abbas MH, Darwish A, Shafeek Z, New J, Ammori BJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis 2011;7:691–696.CrossRefPubMed
42.
Zurück zum Zitat Blackstone R, Bunt JC, Cortes MC, Sugerman HJ. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis 2012;8:548–555.CrossRefPubMed Blackstone R, Bunt JC, Cortes MC, Sugerman HJ. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis 2012;8:548–555.CrossRefPubMed
43.
Zurück zum Zitat Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol 2014;2:38–45.CrossRefPubMedCentralPubMed Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol 2014;2:38–45.CrossRefPubMedCentralPubMed
44.
Zurück zum Zitat Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–1348.CrossRefPubMed Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–1348.CrossRefPubMed
45.
Zurück zum Zitat Lee WJ, Wang W, Lee YC, et al. Effects of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI > 35 and < 35 Kg/m2. J Gastrointest Surg 2008;12:945–952.CrossRefPubMed Lee WJ, Wang W, Lee YC, et al. Effects of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI > 35 and < 35 Kg/m2. J Gastrointest Surg 2008;12:945–952.CrossRefPubMed
46.
Zurück zum Zitat Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012;18:49–54.CrossRefPubMedCentralPubMed Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012;18:49–54.CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Lee WJ, Chong K, Ser KH, et al. C-peptide Predicts the Remission of Type 2 Diabetes after Bariatric Surgery. Obesity Surgery 2012; 22:293–298.CrossRefPubMed Lee WJ, Chong K, Ser KH, et al. C-peptide Predicts the Remission of Type 2 Diabetes after Bariatric Surgery. Obesity Surgery 2012; 22:293–298.CrossRefPubMed
48.
Zurück zum Zitat Aarts EO, Janssen J, Janssen IM, Berends FJ, Telting D, de Boer H. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg 2013;23:867–873.CrossRefPubMed Aarts EO, Janssen J, Janssen IM, Berends FJ, Telting D, de Boer H. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg 2013;23:867–873.CrossRefPubMed
49.
Zurück zum Zitat Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–234.CrossRef Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–234.CrossRef
50.
Zurück zum Zitat Carrison LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Sweden obese subjects. NEJM 2012;367:2683–2693. Carrison LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Sweden obese subjects. NEJM 2012;367:2683–2693.
51.
Zurück zum Zitat Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518–25.CrossRefPubMed Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518–25.CrossRefPubMed
52.
Zurück zum Zitat DePaula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22(12):2670–8.CrossRefPubMed DePaula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22(12):2670–8.CrossRefPubMed
53.
Zurück zum Zitat Ramos AC, Galvao N, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 Kg/m2 (LBMI). Obes Surg 2009;19:307–311.CrossRefPubMed Ramos AC, Galvao N, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 Kg/m2 (LBMI). Obes Surg 2009;19:307–311.CrossRefPubMed
Metadaten
Titel
Predictors of Long-Term Diabetes Remission After Metabolic Surgery
verfasst von
Ming Hsien Lee
Wei-Jei Lee
Keong Chong
Jung-Chien Chen
Kong-Han Ser
Yi-Chih Lee
Shu-Chun Chen
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 6/2015
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2808-1

Weitere Artikel der Ausgabe 6/2015

Journal of Gastrointestinal Surgery 6/2015 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.